Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Chronic low-grade inflammation in vegetarians and vegans: Biomarker evidence and methodological considerations.

Advances in clinical chemistry·2026

Same author

Corrigendum to 'Cytogenotoxic effects of polycyclic aromatic hydrocarbons complex mixture in human peripheral blood, lung A549 and liver HepG2 cells: Translation of a real-scenario exposure to in vitro' [Environ. Res. 298 (2026) 124252].

Environmental research·2026

Same author

Oxide-nanoparticles induce in vitro DNA damage and genomic instability in human peripheral blood cells.

Mutation research. Genetic toxicology and environmental mutagenesis·2026

Same author

The comet assay as a tool for human biomonitoring of exposure to environmental and occupational agents - A summary of systematic reviews and meta-analyses.

Mutation research. Reviews in mutation research·2026

Same author

DNA Damage Across Dietary Patterns: A Comet Assay Study in Vegans and Omnivores.

Foods (Basel, Switzerland)·2026

Same author

Comparative Evaluation of Machine Learning Models for Residential PM<sub>1</sub> Prediction in Zagreb (Croatia): Identifying Key Predictors and Indoor/Outdoor Dynamics.

Toxics·2026

Search research articles

Related Experiment Video

Updated: May 9, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Melittin: a lytic peptide with anticancer properties.

Goran Gajski¹, Vera Garaj-Vrhovac¹

¹Institute for Medical Research and Occupational Health, Mutagenesis Unit, 10000 Zagreb, Croatia.

Environmental Toxicology and Pharmacology

|July 30, 2013

Summary

Melittin, a bee venom peptide, shows anticancer potential by inducing cancer cell death. Nanoparticle delivery systems are crucial for its safe and effective use in cancer therapy, targeting tumors while minimizing harm to normal cells.

Keywords:

Anticancer effect Apoptosis Bee venom Melittin Necrosis Tumour cells

More Related Videos

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

Related Experiment Videos

Last Updated: May 9, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

Area of Science:

Biochemistry
Pharmacology
Oncology

Background:

Melittin (MEL), a primary component of bee venom, is recognized for its cytotoxic effects on various cancer cell types.
Observed mechanisms include cell cycle disruption, proliferation inhibition, and the induction of apoptosis and necrosis via caspase and matrix metalloproteinase activation.
Despite its broad-spectrum tumor cell cytotoxicity, MEL also exhibits toxicity to normal cells, posing a challenge for therapeutic application.

Purpose of the Study:

To review the current understanding and recent findings on the anticancer potential of melittin.
To explore the mechanisms by which melittin exerts its cytotoxic effects on cancer cells.
To discuss the role of nanoparticle-based delivery systems in overcoming the challenges associated with melittin's therapeutic use.

Main Methods:

Literature review of existing research on melittin's anticancer properties.
Analysis of studies detailing melittin's cytotoxic mechanisms in cancer cells.
Examination of research on melittin-loaded nanoparticles for targeted cancer therapy.

Main Results:

Melittin demonstrates significant cytotoxicity against a wide range of tumor cells through various cell death pathways.
Nanoparticle formulations of melittin show promise for safe intravenous delivery and targeted tumor elimination.
Development of effective delivery vehicles is essential to harness melittin's therapeutic potential while mitigating systemic toxicity.

Conclusions:

Melittin is a promising lytic peptide with diverse anticancer functions.
Nanotechnology offers a viable strategy to enhance the safety and efficacy of melittin in cancer treatment.
Further research into melittin-based therapies, particularly with advanced delivery systems, is warranted for clinical translation.